Zobrazeno 1 - 10
of 164
pro vyhledávání: '"T Hakes"'
Autor:
David T. Hakes
Not very many years ago, it was common for language researchers and theorists to argue that language development was somehow special and separate from other aspects of development. It was a period when the'1 ittle 1 inguist'view of language developme
Autor:
P. Forsythe, John Crown, Violante Currie, Andrew D. Seidman, José Baselga, Theresa Gilewski, Bonnie Reichman, Clifford A. Hudis, T Hakes, Tzy-Jyun Yao
Publikováno v:
Journal of Clinical Oncology. 13:1152-1159
PURPOSE Two phase II clinical trials were performed to determine efficacy and tolerability of paclitaxel (Taxol; Bristol-Myers Squibb Co, Wallingford, CT) and granulocyte colony-stimulating factor ([G-CSF] Neupogen; Amgen, Inc, Thousand Oaks, CA) as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d38a14f3be16a20c3cce93d4c49db92
https://doi.org/10.1200/jco.1995.13.5.1152
https://doi.org/10.1200/jco.1995.13.5.1152
Autor:
Maurie Markman, Walter B. Jones, William J. Hoskins, Richard Barakat, T Hakes, John L. Lewis, John P. Curtin, Lois Almadrones, Bonnie Reichman, Stephen C. Rubin
Publikováno v:
Journal of Clinical Oncology. 10:1479-1484
PURPOSE To evaluate the impact on survival of the attainment of surgically defined favorable responses (S-R) to salvage intraperitoneal (IP) chemotherapy after initial systemic cytotoxic drug delivery. PATIENTS AND METHODS We examined the survival of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a9a78e2c21d5424179c37653c0fddc
https://doi.org/10.1200/jco.1992.10.9.1479
https://doi.org/10.1200/jco.1992.10.9.1479
Autor:
John L. Lewis, E Rowinsky, Walter B. Jones, Bonnie Reichman, Stephen C. Rubin, M. Phillips, T Hakes, Richard Barakat, John P. Curtin, Maurie Markman
Publikováno v:
Journal of Clinical Oncology. 10:1485-1491
PURPOSE To evaluate the safety and pharmacology of the intraperitoneal (IP) administration of the antineoplastic agent taxol. PATIENTS AND METHODS Twenty-five pretreated patients who were entered onto a phase I clinical trial; 24 had advanced ovarian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19adb3b75ac5583ec2801e4f0cd602ef
https://doi.org/10.1200/jco.1992.10.9.1485
https://doi.org/10.1200/jco.1992.10.9.1485
Autor:
T Hakes, William J. Hoskins, Maurie Markman, Stephen C. Rubin, Bonnie Reichman, John L. Lewis, Walter B. Jones, Lois Almadrones
Publikováno v:
Journal of Clinical Oncology. 9:1801-1805
Phase II trials of second-line intraperitoneal (IP) cisplatin-based therapy in patients with ovarian cancer have demonstrated the ability of this approach to produce objective antitumor responses, including surgically defined complete responses (CRs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70127833b6bbe3a76e38d28d12d31d0e
https://doi.org/10.1200/jco.1991.9.10.1801
https://doi.org/10.1200/jco.1991.9.10.1801
Autor:
Bonnie Reichman, George J. Bosl, Mark G. Kris, Nicholas Iannotti, Maurie Markman, Ephraim S. Casper, Dean F. Bajorin, Magill G, Robert D'Acquisto, Amy Budnick, T Hakes
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 117:151-155
Previous pharmacological and clinical data have suggested that it is possible to increase significantly the dose of "active" cisplatin delivered systemically by the simultaneous administration of intravenous sodium thiosulfate. In order to define mor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab50675d48d0a3fba96582680f6fc0d7
https://doi.org/10.1007/bf01613139
https://doi.org/10.1007/bf01613139
Autor:
John L. Lewis, E.L. Yordan, Maurie Markman, Bonnie Reichman, William J. Hoskins, J.H. Eriksson, Walter B. Jones, T Hakes, Lois Almadrones, Stephen C. Rubin
Publikováno v:
Journal of Clinical Oncology. 9:204-210
Preclinical evaluation has suggested impressive concentration-dependent cytotoxic synergy between cisplatin and cytarabine in ovarian carcinoma. To further evaluate the clinical relevance of these observations, 39 patients with refractory or recurren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9530aa4d2f3727e6bf5f9ac76f7ad140
https://doi.org/10.1200/jco.1991.9.2.204
https://doi.org/10.1200/jco.1991.9.2.204
Autor:
Violante Currie, M. Gollub, David Lebwohl, John Crown, M. Robles, R. Freilich, Theresa Gilewski, T Hakes, José Baselga, George Raptis, Andrew D. Seidman, Casilda Balmaceda, Clifford A. Hudis, Rene Bruno, Larry Norton
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 14(1)
PURPOSE Because docetaxel (Taxotere, RP 56976; Rhone-Poulenc Rorer, Antony, France) appeared to be active against breast cancer in phase I trials, we performed this phase II study. PATIENTS AND METHODS Thirty-seven patients with measurable disease we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b95800a21ab75849b49cd0c317230e76
https://pubmed.ncbi.nlm.nih.gov/8558221
https://pubmed.ncbi.nlm.nih.gov/8558221
Publikováno v:
Scopus-Elsevier
PURPOSE This study was designed to define the maximum-tolerated dose (MTD) and pharmacology of paclitaxel administered by the intraperitoneal (IP) route on a weekly schedule. PATIENTS AND METHODS Thirty-three patients with residual ovarian cancer fol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d337f2de4f8ef794c74f9f03c87554f
https://pubmed.ncbi.nlm.nih.gov/8523061
https://pubmed.ncbi.nlm.nih.gov/8523061
Autor:
David R. Spriggs, C. Bengala, Malcolm A.S. Moore, T Hakes, John P. Curtin, Lilian Reich, Richard R. Barakat, J Schneider, William J. Hoskins, David Fennelly
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 13(5)
PURPOSE We commenced a phase I study of escalating dose Taxol (paclitaxel; Bristol-Myers Squibb Co, Wallingford, CT) in addition to cyclophosphamide, to assess its impact on both antitumor efficacy and mobilization of peripheral-blood progenitor cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ce6769ad7441f2b2715eda61742cde
https://pubmed.ncbi.nlm.nih.gov/7537799
https://pubmed.ncbi.nlm.nih.gov/7537799